APTOSE BIOSCIENCES INC (APTO)

CA03835T3091 - Common Stock

1.66  +0.16 (+10.67%)

After market: 1.61 -0.05 (-3.01%)

News Image
2 days ago - InvestorPlace

APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023

APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.

News Image
2 days ago - BusinessInsider

APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aptose Biosciences (NASDAQ:APTO) just reported results for the fourth quarter o...

News Image
2 days ago - Aptose Biosciences, Inc.

Aptose Reports Results for the Fourth Quarter and Full Year 2023

Aptose Reports Results for the Fourth Quarter and Full Year 2023 ...

News Image
10 days ago - Aptose Biosciences, Inc.

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024 ...

News Image
2 months ago - InvestorPlace

Levi Strauss Layoffs 2024: What to Know About the Latest LEVI Job Cuts

Levi Strauss layoffs are coming for as much as 15% of its corporate workforce as it prepares for a rough economy in 2024!

News Image
2 months ago - InvestorPlace

Why Is SU Group (SUGP) Stock Moving Today?

SU Group stock volatile on Friday following the company's IPO earlier this week with shares currently trading below its debut price.

News Image
2 months ago - InvestorPlace

Why Is Aptose Biosciences (APTO) Stock Down Today?

Aptose Biosciences stock is sliding lower on Friday as investors react to a public offering and private placement for APTO shares.

News Image
2 months ago - Aptose Biosciences, Inc.

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical ...

News Image
2 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning!

News Image
4 months ago - Aptose Biosciences, Inc.

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

ASH Oral Presentation: Complete Response Data from the Ongoing APTIVATE Phase 1/2 Study of Tuspetinib (TUS) in R/R AML Patients...

News Image
4 months ago - Seeking Alpha

Aptose Biosciences files to sell ordinary shares, warrants (NASDAQ:APTO)

Aptose Biosciences (APTO) Friday filed a prospectus related to the proposed sale of its 4.09M ordinary shares and pre-funded warrants. This prospectus is not an

News Image
5 months ago - Aptose Biosciences, Inc.

Aptose Reports Results for the Third Quarter 2023

News Image
5 months ago - Aptose Biosciences, Inc.

Aptose Reports Results for the Third Quarter 2023

Aptose Reports Results for the Third Quarter 2023 • TUS/VEN Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path...

News Image
5 months ago - Aptose Biosciences, Inc.

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

Data from the Ongoing APTIVATE International Phase 1/2 Study in Relapsed/Refractory AML Patients

News Image
5 months ago - Aptose Biosciences, Inc.

Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients ...

News Image
5 months ago - Aptose Biosciences, Inc.

Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023

Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023 ...

News Image
5 months ago - Aptose Biosciences, Inc.

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

Aptose to Hold Clinical Update Webcast and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th ...

News Image
5 months ago - Aptose Biosciences, Inc.

Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

Company to Hold Clinical Update Webcast; Details Forthcoming

News Image
5 months ago - Aptose Biosciences, Inc.

Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

Aptose to present TUS/VEN AML data at ESH; to hold clinical update webcast on October 30th. TUS appears to re-sensitize Prior-VEN failure patients to...

News Image
6 months ago - Aptose Biosciences, Inc.

Aptose to Present at the Cantor Global Healthcare Conference

SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage...

News Image
7 months ago - Aptose Biosciences, Inc.

Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical

— TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax —...